About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« ". . .And to Furbish Falsehoods For a Magazine" | Main | Here and There »

September 13, 2005

It Pours on Ligand

Email This Entry

Posted by Derek

Pfizer and Ligand had their application for Oporia (lasofoxifene) shot down by the FDA this week. Details are scarce about the grounds for this action, but lasofoxifene was supposed to be one of Pfizer's string of billion-dollar drugs - you know, the ones that they need every single one of to meet their growth targets. It's a selective estrogen receptor modulator (SERM) for osteoporosis, a useful therapeutic niche which at present is pretty much owned by Lilly.

And it's a hard area to make a living in. Nuclear receptors are wonderfully interesting things, and they're wonderfully complex if you're doing basic research on them. If you're doing applied research, on the other hand, they're hideously complex - same coin, different sides. There's a large family of NRs, including the PPARs that I was speaking about a few days ago, the steroid receptors, and many other odds and ends.

They all work at the gene transcription level, and they're one of the few ways that we can mess with that world through small drug-like molecules. Many nuclear receptors can bind small molecules (like a steroid or fatty acid), and that sets off a complicated chain of events. They then often pick up another nuclear receptor protein in a sort of face-to-face binding, and that other protein one can be another of its own type or a different one. (The various retinoic acid receptors are particularly known for heterodimerizing with other members of the family.)

Then that beast picks up a number of other proteins, forming a very large complex, and this is where we lose our ability to understand what's going on. These cofactors are involved in the binding of the whole complex to stretches of DNA (a closeup view) and its subsequent readout into messenger RNA. But some of them seem to inhibit this process, and some to enhance it. To make things more interesting, the nuclear receptor complex can bind to dozens (hundreds?) of different genes, and the cofactors can switch roles (promoter, inhibitor) depending on which one they're involved with. We don't know how many different cofactors there are - a bunch, that's for sure - and different types of cells can have very different suites of them available. (Those profiles change with time and the external environment, too.) Here's an extremely well-done Flash lecture from the comprehensive NURSA site if you want to become an instant nuclear receptor nerd. I took the step several years ago, myself, when it had to be done by hand, sonny.

All this variability makes it foolhardy to generalize about nuclear receptor actions. If you say that Cofactor X is a transcriptional inhibitor, someone can come up with a system where it does the opposite. If you say that Nuclear Receptor Y is responsible for the transcriptional regulation of Gene Z, someone can show you a cell line where it has nothing to do with it, or where it does the reverse of what it does in yours. That's how the Selective Estrogen Receptor Modulators (SERMs) work. The ones you want work in opposite ways in bone tissue versus breast tissue, and if the signaling pathways were simple, that probably wouldn't be possible. This particular split seems to work through the different cofactor profile mechanism.

The complexity of the field has made some companies just throw up their hands and decide to spend their money somewhere else. For the same reasons, it's made others decide to concentrate only on that area, and Ligand is the best example. It's been quite a rough ride for them over the years. They've had (and still have) deals with several major companies, and have had all sorts of things go into development, but there haven't been any home runs yet. Worse, they're in the middle of some accounting problems (to put the matter delicately) that have led to an SEC investigation and their stock being recently delisted from NASDAQ. No, tedium has not been a big problem.

Comments (0) + TrackBacks (0) | Category:


Remember Me?


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry